Inventor · disambiguated record
Matthew B. Jarpe
Also filed as: JARPE MATTHEW · JARPE MATTHEW B · JARPE MATTHEW BLAIR
5 granted patents·18 pending applications·61 citations·filing 2006–2022
79Inventor score
Files withKORRO BIO INC10REGENACY PHARMACEUTICALS LLC7ACETYLON PHARMACEUTICALS INC3BIOGEN IDEC INC2JONES SIMON S1
Top patents by PatentIndex Score
23 records- 0192US7422899B2Antibodies to the human prolactin receptorBIOGEN IDEC INC·Filed 2006·Granted Sep 9, 2008·47 cites·13 claims
- 0287US10858323B2HDAC inhibitors for the treatment of diabetic peripheral neuropathyREGENACY PHARMACEUTICALS LLC·Filed 2018·Granted Dec 8, 2020·5 cites·4 claims
- 0385US10040769B2HDAC inhibitors for the treatment of diabetic peripheral neuropathyACETYLON PHARMACEUTICALS INC·Filed 2016·Granted Aug 7, 2018·8 cites·2 claims
- 0471US10272084B2Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathyREGENACY PHARMACEUTICALS LLC·Filed 2016·Granted Apr 30, 2019·1 cites·6 claims
- 0565US11013740B2Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathyREGENACY PHARMACEUTICALS LLC·Filed 2019·Granted May 25, 2021·0 cites·5 claims
- 0664US2023257752A1Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)KORRO BIO INC·Filed 2022·Application pending·0 cites
- 0764US2023272376A1Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)KORRO BIO INC·Filed 2022·Application pending·0 cites
- 0864US2023295664A1Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)KORRO BIO INC·Filed 2022·Application pending·0 cites
- 0964US2023295614A1Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)KORRO BIO INC·Filed 2022·Application pending·0 cites
- 1064US2023272384A1Methods and compositions for the adar-mediated editing of retinochisin 1 (rs1)KORRO BIO INC·Filed 2022·Application pending·0 cites
- 1164US2023212569A1Methods and compositions for the adar-mediated editing of otoferlin (otof)KORRO BIO INC·Filed 2022·Application pending·0 cites
- 1264US2023272377A1Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)KORRO BIO INC·Filed 2022·Application pending·0 cites
- 1364US2023272383A1Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)KORRO BIO INC·Filed 2022·Application pending·0 cites
- 1460US2021251990A1Histone Deacetylase 6 Selective Inhibitors for the Treatment of Cisplatin-Induced Peripheral NeuropathyREGENACY PHARMACEUTICALS LLC·Filed 2021·Application pending·0 cites
- 1560US2021155593A1Hdac inhibitors for the treatment of diabetic peripheral neuropathyREGENACY PHARMACEUTICALS LLC·Filed 2020·Application pending·0 cites
- 1657US2023174989A1Methods and Compositions for the ADAR-Mediated Editing of ABCA4KORRO BIO INC·Filed 2021·Application pending·0 cites
- 1757US2025352667A1Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editingKORRO BIO INC·Filed 2022·Application pending·0 cites
- 1855US2009017044A1Antibodies to the Human Prolactin ReceptorBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 1946US2021332036A1Pyrimidine and pyrazine hdac1,2 inhibitorsREGENACY PHARMACEUTICALS LLC·Filed 2019·Application pending·0 cites
- 2039US2013225543A1Specific regulation of cytokine levels by hdac6 inhibitorsJONES SIMON S·Filed 2013·Application pending·0 cites
- 2136US2016228434A1Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitorACETYLON PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2235US2017240535A1Hdac1/2 inhibitors for the treatment of neurodegenerative and/or cognitive disordersREGENACY PHARMACEUTICALS LLC·Filed 2017·Application pending·0 cites
- 2326US2016137630A1Induction of gata2 by hdac1 and hdac2 inhibitorsACETYLON PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthew B. Jarpe files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →